Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicine and to be Presented During Presidential Symposium at the 24 th European Hematology Association (EHA) Congress Additional Clinical Data

Company Created ACCEL (Access to Excellent Care for Sickle Cell Patients Pilot Program) to Accelerate Development of Innovative Healthcare Programs for Sickle Cell Community SOUTH SAN FRANCISCO, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , June 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2019 , the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the

Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort  to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor to Include HOPE Study Data Being Presented at EHA 2019 Company to Host Investor Webcast on Friday, June 14 SOUTH SAN

SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2019. “With a goal of getting voxelotor to the sickle cell community as quickly as

SOUTH SAN FRANCISCO, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2019 , the compensation committee of GBT’s board of directors granted nine new employees options to purchase an aggregate of 24,600 shares of the

SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2019 , the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units representing an aggregate of 30,500

SOUTH SAN FRANCISCO, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 , at 10:10 a.m. British Summer Time.

SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019 , the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 76,100 shares of the

SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39 th Annual Health Care Conference in Boston on Monday, March 11, 2019 , at 4:50 p.m. Eastern Time .

Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today

SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019 , at 1 p.m. Eastern Time .

—The Access to Excellent Care for Sickle Cell Patients Pilot Program ( ACCEL ) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease— —GBT Will Fund Proposals With the Highest Potential to Impact Patient Care— SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2019 , the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 21,850 shares of the

—Company Plans to Submit NDA for Voxelotor Under FDA Accelerated Approval Pathway Later This Year— SOUTH SAN FRANCISCO, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with

SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on January 1, 2019 , the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate

SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 , at 11:30 a.m. Pacific Time .